Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes is a clinical-stage biopharmaceutical company created by and for this moment to solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to develop novel drugs while reimagining the patient journey to access these medicines.

Learn More

Stock
Quote

Volume:

03/07/2023 8:51 AMEST

Press
Releases

03/14/2023

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

02/01/2023

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

11/07/2022

Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

11/01/2022

Pardes Biosciences to Present at Jefferies London Healthcare Conference

Webcasts

Financial Information

Document Date	Description	Form	View
12/31/2021	Annual report which provides a comprehensive overview of the company for the past year	10-K	View HTML 0000950170-22-004946.pdf 0000950170-22-004946.rtf 0000950170-22-004946.xls EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
12/31/2022	Annual report which provides a comprehensive overview of the company for the past year	10-K	View HTML 0000950170-23-007860.pdf 0000950170-23-007860.rtf 0000950170-23-007860.xls EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
03/31/2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001213900-21-027060.pdf 0001213900-21-027060.rtf 0001213900-21-027060.xls EX-101.INS - XBRL INSTANCE FILE
06/30/2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001213900-21-042747.pdf 0001213900-21-042747.rtf 0001213900-21-042747.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
09/30/2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001213900-21-058296.pdf 0001213900-21-058296.rtf 0001213900-21-058296.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
03/31/2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-22-008983.pdf 0000950170-22-008983.rtf 0000950170-22-008983.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
06/30/2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-22-017368.pdf 0000950170-22-017368.rtf 0000950170-22-017368.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
09/30/2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-22-022581.pdf 0000950170-22-022581.rtf 0000950170-22-022581.xls EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
09/30/2021	Amendment to a previously filed 10-Q	10-Q/A	View HTML 0001213900-21-061618.pdf 0001213900-21-061618.rtf 0001213900-21-061618.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009867.pdf 0001213900-21-009867.rtf 0001213900-21-009867.xls

Contact
IR

Send us an investor-related question using the form below.